08:19 AM EDT, 10/21/2025 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Tuesday it has closed a global licensing and collaboration agreement with Novartis ( NVS ) for ARO-SNCA preclinical RNA interference therapy to potentially treat patients with Parkinson's disease and other synucleinopathies.

Under the deal, Arrowhead said it will receive a $200 million upfront payment and would be eligible for up to $2 billion in additional milestone payments as well as tiered royalties on commercial sales.

Arrowhead said it will complete preclinical work to support a clinical trial application filing, after which Novartis ( NVS ) will assume sole control over development, manufacturing, medical affairs, and commercialization.

Shares of Arrowhead Pharmaceuticals ( ARWR ) were up more than 1% in recent Tuesday premarket activity, while Novartis ( NVS ) stock was down 0.5%.